ReviewFrontiers in nutrition2026
Short-chain fatty acids in ulcerative colitis: integrating metabolic fate, dynamic biomarkers, and precision delivery.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is characterized by gut dysbiosis and impaired mucosal metabolism, positioning short-chain fatty acids (SCFAs) as pivotal mediators. This review moves beyond general mechanisms, offering an in-depth analysis of SCFA metabolic fate, including specific transporters (e.g., monocarboxylate transporter 1 (MCT1) and sodium-coupled monocarboxylate transporter 1 (SMCT1)), the concept of "colon fuel priority," and their systemic distribution bypassing first-pass hepatic metabolism to reach distant organs. We integrate the established role of SCFAs in modulating immunity and barrier function with their significant but lesser-discussed effects on attenuating oxidative stress and regulating colonic motility. Crucially, we highlight SCFAs' emergence as dynamic metabolic "fingerprints" with significant diagnostic and prognostic potential, offering advantages over conventional inflammatory markers. The therapeutic section emphasizes novel strategies, from microbiota-targeted approaches to the urgent need for efficient, site-specific delivery systems. By systematically bridging deep mechanistic understanding, biomarker utility, and innovative delivery platforms, this review advances SCFA-centered nutritional strategies toward precise and individualized management of UC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.